ACLX - Arcellx, Inc.

Arcellx, Inc. , a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).

Sector

Healthcare

Industry

Biotechnology

Market Cap

$6.73B

Beta

0.25

52-Week Range

50.85-115.13

CEO

Rami Elghandour

Employees

163

IPO Date

Feb 4, 2022

Exchange

NASDAQ

ACLX Options Snapshot

Options pricing data for ACLX is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.

What This Page Covers

The ACLX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.